HODGKIN DISEASE
Clinical trials for HODGKIN DISEASE explained in plain language.
Never miss a new study
Get alerted when new HODGKIN DISEASE trials appear
Sign up with your email to follow new studies for HODGKIN DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lymphoma drug combo trial for youth halted after just 5 patients
Disease control TerminatedThis early-phase trial tested a combination of two immune-boosting drugs, relatlimab and nivolumab, in children and young adults with Hodgkin or non-Hodgkin lymphoma that had come back or not responded to treatment. The goal was to check safety, drug levels, and whether the tumor…
Matched conditions: HODGKIN DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New lymphoma drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug, PF-08046044/SGN-35C, in people with advanced lymphomas (Hodgkin and non-Hodgkin types) who had no other treatment options. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: HODGKIN DISEASE
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New pill for tough blood cancers tested in early trial
Disease control TerminatedThis early-stage study tested an oral drug called AUR104 in 9 adults with certain blood cancers (lymphomas and leukemia) that had come back or stopped responding to treatment. The main goal was to check the drug's safety and how the body processes it. The trial was terminated ear…
Matched conditions: HODGKIN DISEASE
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New lymphoma drug trial halted early
Disease control TerminatedThis study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.
Matched conditions: HODGKIN DISEASE
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New hope for kids after transplant: study tests safer GVHD prevention
Disease control TerminatedThis study looked at a new way to prevent severe graft-versus-host disease (GVHD) in children who had a bone marrow transplant for blood cancers. The goal was to see if stopping certain immune-suppressing drugs after day 60 could lower the risk of severe GVHD. Only 3 children too…
Matched conditions: HODGKIN DISEASE
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC